# US 2010/0137197 A1 · Lyophilized anti-fungal composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137197 A1
- Document ID: US20100137197A1
- Status: Published application
- Kind: A1
- Application number: 12/666,426
- Filed: 2008-06-23
- Published: 2010-06-03
- Earliest claimed: 2007-06-26
- Inventors: Sachin Mittal; Hossain Jahansouz; Suttilug Sotthivirat
- Web page: https://patentgrep.com/patent/US20100137197A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.

## Claims

### Claim 1

A lyophilized anti-fungal composition which comprises:
(A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount;
(B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and
(C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7;
wherein:
the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1;
the composition has a moisture content of about 0.8 wt. % or less; and
the composition has a glass transition temperature Tg(c) of at least about 55° C.

### Claim 2 (depends on 1)

The lyophilized composition according to claim 1, wherein trehalose is the non-reducing sugar.

### Claim 3 (depends on 2)

The lyophilized composition according to claim 2, wherein the moisture content of the composition is about 0.5 wt. % or less and the glass transition temperature Tg(c) of the composition is at least about 90° C.

### Claim 4 (depends on 1)

The lyophilized composition according to claim 1, which is prepared by lyophilizing an aqueous solution comprising the caspofungin or its salt, the acetate buffer, and the one or more non-reducing sugars, wherein in the solution:
(A) the caspofungin or its salt has a concentration in a range of from about 5 mg/mL to about 200 mg/mL;
(B) the one or more non-reducing sugars has a concentration ratio on a mg/mL basis with respect to caspofungin in a range of from about 2:1 to about 10:1; and
(C) the acetate buffer has a concentration in a range of from about 12.5 mM to about 200 mM.

### Claim 5 (depends on 4)

The lyophilized composition according to claim 4, wherein trehalsoe is the non-reducing sugar, the moisture content of the lyophilized composition is about 0.5 wt. % or less, and the glass transition temperature Tg(c) of the lyophilized composition is at least about 90° C.

### Claim 6 (depends on 5)

The lyophilized composition according to claim 5, wherein in the aqueous solution from which the lyophilized composition is prepared:
(A) the concentration of caspofungin or its salt is in a range of from about 30 mg/mL to about 50 mg/mL;
(B) the concentration ratio of trehalose to caspofungin is in a range of from about 4:1 to about 8:1; and
(C) the concentration of the acetate buffer is in a range of from about 20 mM to about 60 mM.

### Claim 7 (depends on 6)

The lyophilized composition according to claim 6, wherein in the aqueous solution from which the lyophilized composition is prepared:
(A) the concentration of caspofungin or its salt is in a range of from about 30 mg/mL to about 50 mg/mL;
(B) the concentration of trehalose is in a range of from about 180 mg/mL to about 300 mg/mL; and
(C) the acetate buffer has a concentration in a range of from about 20 mM to about 60 mM.

### Claim 8

A process for preparing a lyophilized anti-fungal composition with a moisture content of less than about 0.8 wt. %, which comprises
(A) preparing an aqueous solution with a pH in a range of from about 5 to about 7 and comprising an effective amount of caspofungin or a pharmaceutically acceptable salt thereof, one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C., and an acetate buffer, wherein the concentration ratio, on a weight per unit volume basis, of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; and
(B) freeze-drying the aqueous solution to provide the lyophilized anti-fungal composition.

### Claim 9 (depends on 8)

The process according to claim 8, wherein Step A further comprises:
(a1) dissolving the one or more non-reducing sugars in water;
(a2) adding acetic acid and then adjusting the pH to be in a range of from about 4.5 to about 5.5 by addition of base;
(a3) adding caspofungin or its salt and adjusting the pH to a value in a range of from about 5 to about 7 by addition of more base; and
(a4) optionally filtering the resulting aqueous solution.

### Claim 10 (depends on 8, 9)

The process according to either claim 8 or claim 9, wherein trehalose is the non-reducing sugar.

### Claim 11 (depends on 10)

The process according to claim 10, wherein in the aqueous solution resulting from Step A the caspofungin or its salt has a concentration in a range of from about 5 mg/mL to about 200 mg/mL, and the concentration ratio of trehalose to caspofungin is in a range of from about 2:1 to about 10:1.

### Claim 12 (depends on 11)

The process according to claim 11, wherein in the aqueous solution resulting from Step A the concentration of caspofungin or its salt is in a range of from about 30 mg/mL to about 50 mg/mL, and the concentration ratio of trehalose to caspofungin is in a range of from about 4:1 to about 8:1.

### Claim 13 (depends on 8, 9, 10, 11, 12)

The process according to any one of claims 8 to 12, wherein the moisture content of the resulting lyophilized composition is about 0.5 wt. % or less.

### Claim 14 (depends on 8, 9, 10, 11, 12, 13)

A lyophilized anti-fungal composition prepared by the process set forth in any one of claims 8 to 13.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 14)

A kit comprising a first container having the lyophilized anti-fungal composition according to any one of claims 1 to 7 and 14 and a second container having a parenterally acceptable solvent for reconstitution thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 14)

A method of preparing an anti-fungal liquid formulation for parenteral administration, which comprises reconstituting the lyophilized anti-fungal composition according to any one of claims 1 to 7 and 14 with a parenterally acceptable solvent to form an anti-fungal solution concentrate and then mixing the concentrate with a diluent comprising water to provide the formulation.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the parenterally acceptable solvent comprises water.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the parenterally acceptable solvent is selected from the group consisting of 0.9% Sodium Chloride Injection, Sterile Water for Injection, Bacteriostatic Water for Injection with methylparaben and propylparaben, and Bacteriostatic Water for Injection with 0.9% benzyl alcohol.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the diluent is 0.9%, 0.45% or 0.225% Sodium Chloride Injection or Lactated Ringer's Injection.

### Claim 20 (depends on 19)

The method according to claim 19 wherein the concentrate contains from about 5 mg/mL to about 8 mg/mL of caspofungin, and the liquid formulation resulting from dilution of the concentrate contains from about 0.2 mg/mL to about 0.5 mg/mL of caspofungin.

### Claim 21 (depends on 16, 17, 18, 19, 20)

An anti-fungal liquid dosage formulation for parenteral administration prepared by the method set forth in any one of claims 16 to 20.

### Claim 22 (depends on 16, 17, 18, 19, 20)

A method for the treatment or prophylaxis of a fungal infection which comprises parenterally administering to a subject in need thereof an anti-fungal liquid dosage formulation prepared by the method set forth in any one of claims 16 to 20.
